iBio Inc IBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.90
- Day Range
- $0.79–0.90
- 52-Week Range
- $0.79–3.82
- Bid/Ask
- $0.79 / $0.80
- Shares Outstanding
- 64.31M
- Market Cap
- $52.54M
- Volume/Avg
- 781,099 / 736,134
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 939.85
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 23
- Website
- https://www.ibioinc.com
Valuation
|
Metric
|
IBIO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.59 |
Price/Sales | 939.85 |
Price/Cash Flow | — |
Price/Earnings
IBIO
Financial Strength
|
Metric
|
IBIO
|
|---|---|
Quick Ratio | 7.59 |
Current Ratio | 7.85 |
Interest Coverage | −663.04 |
Quick Ratio
IBIO
Profitability
|
Metric
|
IBIO
|
|---|---|
Return on Assets (Normalized) | −39.45% |
Return on Equity (Normalized) | −45.68% |
Return on Invested Capital (Normalized) | −47.06% |
Return on Assets
IBIO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|G$Mvvb% | LOCK|rx^PL | $129B | |||
| Moderna Inc
MRNA
| LOCK|!&<n@m | LOCK|R&K | $85B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&?&XDSd | LOCK|B#J&X | $79B | |||
| argenx SE ADR
ARGX
| LOCK|Y%#%Bfd | LOCK|!? | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|ZZw<!&w | LOCK|!cq | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|h^#hT> | LOCK|j??b | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|y@#y!kb? | LOCK|w&D% | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|?&K#Nrx | LOCK|fnh | $24B | |||
| Incyte Corp
INCY
| LOCK|LC?ZCWN | LOCK|mc< | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|b!?<X$? | LOCK|VG! | $14B |
United States